Kevin Fitzgerald - 23 Feb 2023 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
Director
Signature
/s/ Danielle Mann for Kevin Fitzgerald by PoA
Issuer symbol
OVID
Transactions as of
23 Feb 2023
Transactions value $
$0
Form type
4
Filing time
27 Feb 2023, 15:51:18 UTC
Previous filing
04 Feb 2022
Next filing
26 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Stock Option (Right to Buy) Award $0 +15K $0.00 15K 23 Feb 2023 Common Stock 15K $2.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest in full on February 23, 2024 subject to the Reporting Person's continuous service through such vesting date.